Caesars Entertainment misses Q2 earnings expectations, shares edge lower
In a challenging market environment, Adc Therapeutics SA (ADCT) stock has reached a 52-week low, trading at $1.42, with a market capitalization of $138 million. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value assessment. The oncology-focused biotechnology company has faced significant headwinds over the past year, reflected in a substantial 1-year decline of 66.28%. With a concerning revenue decline of 42.3% and negative gross profit margins, investors have shown increasing concern. InvestingPro subscribers have access to 10+ additional key insights about ADCT’s financial health and future prospects. The company, known for its targeted therapies for patients with hematological malignancies and solid tumors, continues to navigate through a tough phase as it seeks to regain its footing in the biotech sector. With a current ratio of 4.92, the company maintains strong liquidity despite operational challenges, though analysts don’t expect profitability this year.
In other recent news, ADC Therapeutics has been the subject of several notable developments. The company has successfully completed enrollment for its LOTIS-5 Phase 3 trial evaluating ZYNLONTA in combination with rituximab for relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). This development led H.C. Wainwright to maintain its Buy rating for ADC Therapeutics’ stock.
In another trial, ADC Therapeutics reported positive preliminary results from the LOTIS-7 Phase 1b trial, which assesses ZYNLONTA in combination with glofitamab. The trial showed a best overall response rate of 94% based on Lugano criteria, with a complete response rate of 72%.
Additionally, ADC Therapeutics’ shareholders have approved an increase in the company’s capital range, as part of amendments to its articles of association. The changes were approved at an extraordinary general meeting and took effect immediately.
These are among the recent developments for ADC Therapeutics, underlining the ongoing progress and strategic decisions within the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.